{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:01:00Z","timestamp":1781456460604,"version":"3.54.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,13]]},"DOI":"10.7759\/cureus.110805","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:42:26Z","timestamp":1781455346000},"source":"Crossref","is-referenced-by-count":0,"title":["Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept"],"prefix":"10.7759","author":[{"given":"Nikos","family":"Adamidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Adamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki E","family":"Georgakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektaria","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Adamidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.77235","article-title":"Cellulite: a cosmetic or systemic issue? Contemporary views on the etiopathogenesis of cellulite","volume":"35","author":"Tokarska K","year":"2018","unstructured":"Tokarska K, Tokarski S, Wo\u017aniacka A, Sysa-J\u0119drzejowska A, Bogaczewicz J. Cellulite: a cosmetic or systemic issue? Contemporary views on the etiopathogenesis of cellulite. Postepy Dermatol Alergol. 2018, 35:442-446. 10.5114\/ada.2018.77235","journal-title":"Postepy Dermatol Alergol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85970","article-title":"Short-term effects of tirzepatide in obese adults: a real-world prospective study","volume":"17","author":"Adamidis N","year":"2025","unstructured":"Adamidis N, Desalermos A, Papadopoulou N, et al.. Short-term effects of tirzepatide in obese adults: a real-world prospective study. Cureus. 2025, 17:e85970. 10.7759\/cureus.85970","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.107081","article-title":"Effects of tirzepatide on body composition, metabolic parameters, and sleep outcomes: a real-world one-year prospective study","volume":"18","author":"Adamidis N","year":"2026","unstructured":"Adamidis N, Margariti T, Georgakopoulou VE, et al.. Effects of tirzepatide on body composition, metabolic parameters, and sleep outcomes: a real-world one-year prospective study. Cureus. 2026, 18:e107081. 10.7759\/cureus.107081","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-216. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503892-cellulite-as-a-possible-biomarker-of-metabolic-dysfunction-redefining-body-remodeling-in-the-glucagon-like-peptide-1-era-through-the-cellulite-removal-medical-protocol-g21-concept","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:42:27Z","timestamp":1781455347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503892-cellulite-as-a-possible-biomarker-of-metabolic-dysfunction-redefining-body-remodeling-in-the-glucagon-like-peptide-1-era-through-the-cellulite-removal-medical-protocol-g21-concept"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.110805","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}